<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23263">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01762813</url>
  </required_header>
  <id_info>
    <org_study_id>29034/2012</org_study_id>
    <nct_id>NCT01762813</nct_id>
  </id_info>
  <brief_title>Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer</brief_title>
  <acronym>ACROBATICC</acronym>
  <official_title>Prospective, Population-based Cohort Collection of Blood Samples and Tumor Tissue From Patients Operated on for Primary or Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helse Stavanger HF</source>
  <oversight_info>
    <authority>Norway: Regional Ethics Commitee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  A prospective, observational study on clinical outcomes of surgical management of
           primary and metastatic colorectal cancer

        -  Prospective collection of tissues to explore potential biomarkers in blood and/or
           primary or secondary cancers and/or normal colon

        -  Prospective collection of patient reported outcome measures (PROMs)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective project in collecting and assessing clinical outcomes data related to molecular
      profiling of tumors based on cancer primary or metastatic tissue or tissue from peripheral
      blood samples. As part of the project will be collected patient reported outcomes (PROs) for
      assessing clinical outcomes in relation to clinical pathways, patient reported results, as
      well as tumor profiling by molecular methods.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Cancer-specific survival</measure>
    <time_frame>5-years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>3 and 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">850</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>colorectal cancer surgery</arm_group_label>
    <description>Patients with primary and or metastic colorectal cancer eligible for curative surgery will be included. Subcohorts may be based on either colon cancer, rectal cancer, metastatic cancer, surgery, node negative and node positive disease, and molecular profiling.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Colorectal cancer surgery</intervention_name>
    <description>Curative surgery for either primary (colorectal cancer) or metastatic CRC (liver surgery)</description>
    <arm_group_label>colorectal cancer surgery</arm_group_label>
    <other_name>Liver metastasis surgery</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, whole blood, plasma, cancer tissue, normal tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with colorectal cancer (primary and/or secondary) undergoing surgery for
        curative intent
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of colorectal cancer

          -  Informed consent to participate

          -  Age ≥18

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kjetil Søreide, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helse Stavanger HF</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanne R. Hagland, PhD</last_name>
    <phone>92297672</phone>
    <phone_ext>47</phone_ext>
    <email>hannehagland@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marianne Berg, PhD</last_name>
    <phone>91106328</phone>
    <phone_ext>47</phone_ext>
    <email>marianne@marianneberg.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <zip>4068</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kjetil Søreide, MD, PhD</last_name>
      <phone>92281557</phone>
      <phone_ext>47</phone_ext>
      <email>ksoreide@mac.com</email>
    </contact>
    <investigator>
      <last_name>Kjetil Søreide, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 5, 2014</lastchanged_date>
  <firstreceived_date>January 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colon cancer</keyword>
  <keyword>rectal cancer</keyword>
  <keyword>liver metastasis</keyword>
  <keyword>survival</keyword>
  <keyword>biomarker</keyword>
  <keyword>molecular profile</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
